Abstract: Provided is a medicinal composition to be topically administered for tooth regeneration therapy, said composition comprising an RNA molecule targeting USAG-1 or a nucleic acid molecule capable of yielding the RNA molecule and a pharmaceutically acceptable carrier.

Abstract: An object of the present invention is to provide a method for determining whether a subject suffers from malignant lymphoma or leukemia and an agent for treating and/or preventing the disease. The present invention relates to a method for assisting in determining whether a subject suffers from, or is likely to suffer from malignant lymphoma or leukemia, comprising: a detection step of detecting at least one of a fusion mutation of a DUX4 gene, an overexpression of a DUX4 gene, and a fusion mutation of an MEF2D gene; and a determination step of determining that the subject suffers from or is likely to suffer from the disease when at least one of the fusion mutations or the overexpression is detected. Moreover, the present invention relates to a pharmaceutical composition comprising a DUX4 inhibitor as an active ingredient, for treating and/or preventing malignant lymphoma or leukemia in a subject having a fusion mutation of a DUX4 gene and an IGH or IGL gene and/or overexpression of a DUX4 gene.

Abstract: A device for isolating periphery circulating tumor cells or rare cells includes a metal filter having depressions that can capture periphery circulating tumor cells or rare cells that are in a body fluid, and pores that are formed at the depressions and that can pass therethrough body fluid cells other than periphery circulating tumor cells or rare cells.

Abstract: The present invention provides a method of confirming the gene expression, useful in the decision of a five year survival rate of a patient with lung cancer and the use of a DNA probe kit in the method. A method useful in the decision of a survival rate of a patient with non-small cell lung cancer comprising confirming the expression strength of at least one gene in lung cancer tissues isolated from the patient.

Abstract: [PROBLEMS] To provide examination methods and reagents able to detect efficiently cancer patients and patients at high risk of cancer. [MEANS FOR SOLVING PROBLEMS] Significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, between non-carcinoma tissues and carcinoma tissues or adenoma tissues were discovered. The discovery is evidently applicable to detect carcinomas and adenomas (except colorectal carcinomas and colorectal adenomas) specifically by assaying a certain range of GlcNAc-6-sulfated sugar residue groups in tissues of patients and in fecal samples. Examination of carcinomas and adenomas is possible by the use of antibodies reacting specifically with GlcNAc-6-sulfated sugar residues specifically synthesized by enzymes present in carcinoma and adenoma tissues.

Abstract: The present invention provides a method of confirming the gene expression, useful in the decision of a five year survival rate of a patient with lung cancer and the use of a DNA probe kit in the method. A method useful in the decision of a survival rate of a patient with non-small cell lung cancer comprising confirming the expression strength of at least one gene in lung cancer tissues isolated from the patient.

Abstract: A polypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below: (a) a polypeptide having the amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide which includes an amino acid sequence including substitution, deletion, insertion or transposition of one or a few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented the formula I: GlcNAc?1-3Gal?1-4GlcNAc??(I) where GlcNAc represents an N-acetyl-glucosamine residue, Gal represents a galactose residue, ? 1-3 represents a ? 1-3 glycosidic linkage, and ? 1-4 represents a ? 1-4 glycosidic linkage.

Abstract: The present invention provides a method of confirming the gene expression, useful in the decision of a five year survival rate of a patient with lung cancer and the use of a DNA probe kit in the method. A method useful in the decision of a survival rate of a patient with non-small cell lung cancer comprising confirming the expression strength of at least one gene selected from the group consisting of in lung cancer tissues isolated from the patient.

Abstract: A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.

Abstract: A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.

Abstract: A polypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below: (a) a polypeptide having the amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide which includes an amino acid sequence including substitution, deletion, insertion or transposition of one or a few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented the formula I: GlcNAc?1-3Gal?1-4GlcNAc??(I) where GlcNAc represents an N-acetyl-glucosamine residue, Gal represents a galactose residue, ? 1-3 represents a ? 1-3 glycosidic linkage, and ? 1-4 represents a ? 1-4 glycosidic linkage.

Abstract: The present inventors introduced mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells, and as a result, demonstrated that the cells induced Epstein-Barr virus-specific cytotoxic T cells. The present inventors also demonstrated that the cytotoxic T cells recognized epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304, inhibited the outgrowth of Epstein-Barr virus-infected B cells, and lysed Epstein-Barr virus-infected NK lymphomas and NK cells.

Abstract: A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.

Abstract: The present invention provides a process for producing a conjugate fiber that is excellent in strength, stretch elasticity, and transparency. The process includes a step (1) in which an elastomer resin (A) having stretching elasticity and an elastomer resin (B) having stretch elasticity, a permanent elongation of 25-70%, and a tensile elongation of 100-800% are separately melted and subjected to conjugate spinning using a conjugate spinneret having two nozzles so that the elastomer resin (A) forms a core and the elastomer resin (B) form a sheath; a step (2) in which the fiber obtained by composite spinning in the step (1) is heat-treated; and a step (3) in which the fiber heat-treated in the step (2) is stretched.

Abstract: The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. The present inventors discovered that there are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore the inventors applied the discovery to diagnosis and found that colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No.

Abstract: It is an object of the present invention to provide a liposome composition which is able to allow the MHC class I and class II molecules of antigen-presenting cells to efficiently present an antigen substance. The present invention provides a liposome composition, which comprises an oligosaccharide-coated liposome and an antigen substance and is used to cause the MHC class I and class II molecules of an antigen-presenting cell to present an antigen peptide.

Abstract: The present invention provides a pharmaceutical composition for ameliorating brain damage induced by oxygen deficiency, comprising a chondroitin sulfate-degrading enzyme and at least one of a neural stem cell(s) and a neural progenitor cell(s), as active ingredients.

Abstract: A method of producing a synthetic board involves the step of heat-pressing a mixture. The mixture includes lignocellulosic material containing lignocellulose and polybutylene succinate-based resin serving as an adhesive.

Abstract: A wooden member fabrication method which, by a simple process, can enable greater stability of shape subsequent to processing and uniformity of color tone. A wooden original piece with a long form has a hole thereinside which extends in the length direction. Corner portions are chamfered and radial direction thicknesses are substantially constrained to a certain range. An outer periphery of this wooden original piece is compression-deformed in directions toward an axial central portion and the outer periphery is thus made an arc surface. Because of the chamfering, radial direction thicknesses of the wooden original piece are constrained, and differences by location between compression ratios can be suppressed.

Abstract: A method for determining the prognosis of a CD5+DLBCL patient and a CD5-DLBCL patient is provided. It is determined that, in the chromosomal DNA from a patient with lymphoma, (1) the prognosis of the CD5+DLBCL patient with amplification of 13q21.1-q31.3 region is poor; (2) the prognosis of the CD5+DLBCL patient with deletion of 1p36.21-p36.13 region is poor; and (3) the prognosis of the CD5-DLBCL patient with amplification of 5p15.33-p14.2 region is good.